Prevnar 13 (PCV13) is produced by Pfizer (formerly Wyeth) and replaced Prevnar. It is a tridecavalent vaccine, it contains thirteen serotypes of pneumococcus (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) which are conjugated to diphtheria carrier protein. Prevnar 13 was approved for use in the European Union in December 2009. On February 2010, Prevnar 13 was approved in the United States to replace the pneumococcal 7-valent conjugate vaccine. After waiting for the outcome of a trial underway in the Netherlands, the Centers for Disease Control and Prevention (CDC) recommended the vaccine for adults over age 65 in August 2014.